It can be suggested that if patients with STGD3 or AMD take enough VLC-PUFAs that the retina can use directly, it might help avoid the processes that ELOVL4 [107] and ELOVL2 [103] support, possibly slowing down or stopping degeneration. This evidence concerns the gene ELOVL2 and age-related macular degeneration.